Details for Patent: 8,507,534
✉ Email this page to a colleague
Which drugs does patent 8,507,534 protect, and when does it expire?
Patent 8,507,534 protects ORKAMBI and is included in two NDAs.
Protection for ORKAMBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty patent family members in twenty-eight countries.
Summary for Patent: 8,507,534
| Title: | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| Abstract: | The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. |
| Inventor(s): | Ali Keshavarz-Shokri, Beili Zhang, Mariusz Krawiec |
| Assignee: | Vertex Pharmaceuticals Inc |
| Application Number: | US12/327,902 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,507,534 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,507,534
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-003 | Sep 2, 2022 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-001 | Aug 7, 2018 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-002 | Aug 7, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | TABLET;ORAL | 206038-002 | Sep 28, 2016 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | TABLET;ORAL | 206038-001 | Jul 2, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,507,534
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2225230 | ⤷ Start Trial | 2017009 | Norway | ⤷ Start Trial |
| European Patent Office | 3170818 | ⤷ Start Trial | 301060 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3170818 | ⤷ Start Trial | PA2020525 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3170818 | ⤷ Start Trial | 122020000044 | Germany | ⤷ Start Trial |
| European Patent Office | 3170818 | ⤷ Start Trial | LUC00172 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3170818 | ⤷ Start Trial | 2020C/005 | Belgium | ⤷ Start Trial |
| European Patent Office | 3170818 | ⤷ Start Trial | CA 2020 00039 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
